WaveMan
WaveMan · Company
SKYE · Skye Bioscience, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SKYE Skye Bioscience (SKYE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001516551
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter

What the filings say about SKYE

Insiders, 180 days
-$889.2K net sold
2 sellers · 0% of sales under a 10b5-1 plan

Skye Bioscience insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Skye Bioscience, Inc. insiders sold a net $889.2K of stock across 63 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
5AM Partners VII, LLC
SELL
2026-09-24 SECtraded 2026-09-23
114,851
$184.9K
-6.0%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 22, 2026.
  • 1 other insider sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider 5AM Partners VII, LLC sold about $184.9K of SKYE on Sep 23, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 9 funds added in the latest 13F quarter.
5AM Partners VII, LLC
SELL
2026-09-24 SECtraded 2026-09-23
4,528
$7.3K
-6.0%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 22, 2026.
  • 1 other insider sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider 5AM Partners VII, LLC sold about $7.3K of SKYE on Sep 23, 2026; 1 other insider sold within 30 days and 9 funds added in the latest 13F quarter.
Schwab Andrew J.
Director
SELL
2026-09-24 SECtraded 2026-09-23
114,851
$184.9K
-6.0%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 22, 2026.
  • 1 other insider sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schwab Andrew J. sold about $184.9K of SKYE on Sep 23, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 9 funds added in the latest 13F quarter.
Schwab Andrew J.
Director
SELL
2026-09-24 SECtraded 2026-09-23
4,528
$7.3K
-6.0%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 22, 2026.
  • 1 other insider sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schwab Andrew J. sold about $7.3K of SKYE on Sep 23, 2026; 1 other insider sold within 30 days and 9 funds added in the latest 13F quarter.
5AM Partners VII, LLC
SELL
2026-09-24 SECtraded 2026-09-22
27,612
$45.6K
-6.0%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Sep 16, 2026.
  • The trade is 24.0% of the 114,851 shares held after it.
  • 1 other insider sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider 5AM Partners VII, LLC sold about $45.6K of SKYE on Sep 22, 2026; 1 other insider sold within 30 days and 9 funds added in the latest 13F quarter.
63 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 58 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$889.2K over 180 days
-$889.2K over 90 days · -$889.2K of it by a 10%+ holder
below 60% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.0% of the float short (float per yahoo 2026-10-26) · 1.7 days to cover · settled 2026-09-30
below 81% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SKYE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+8.3%12M
-61%+30%+120%+210%2025-102025-122026-022026-042026-062026-082026-10 2026-09-23 · 5AM Partners VII, LLC sold $184.9K2026-09-23 · Schwab Andrew J. sold $184.9K2026-08-18 · 5AM Partners VII, LLC sold $96.2K2026-08-18 · Schwab Andrew J. sold $96.2K2026-09-16 · 5AM Partners VII, LLC sold $62.3K2026-09-16 · Schwab Andrew J. sold $62.3K2026-09-22 · 5AM Partners VII, LLC sold $45.6K2026-09-22 · Schwab Andrew J. sold $45.6K2026-08-19 · 5AM Partners VII, LLC sold $20.1K2026-08-19 · Schwab Andrew J. sold $20.1K2026-08-18 · 5AM Partners VII, LLC sold $17.1K2026-08-18 · Schwab Andrew J. sold $17.1K2026-09-23 · 5AM Partners VII, LLC sold $7.3K2026-09-23 · Schwab Andrew J. sold $7.3K2026-08-19 · 5AM Partners VII, LLC sold $3.6K2026-08-19 · Schwab Andrew J. sold $3.6K2026-09-16 · 5AM Partners VII, LLC sold $2.5K2026-09-16 · Schwab Andrew J. sold $2.5K2026-08-20 · 5AM Partners VII, LLC sold $2.1K2026-08-20 · Schwab Andrew J. sold $2.1K2026-09-22 · 5AM Partners VII, LLC sold $1.8K2026-09-22 · Schwab Andrew J. sold $1.8K2026-08-18 · 5AM Partners VII, LLC sold $6952026-08-18 · Schwab Andrew J. sold $6952026-08-20 · 5AM Partners VII, LLC sold $3712026-08-20 · Schwab Andrew J. sold $3712026-08-19 · 5AM Partners VII, LLC sold $1432026-08-19 · Schwab Andrew J. sold $1432026-08-20 · 5AM Partners VII, LLC sold $152026-08-20 · Schwab Andrew J. sold $15
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SKYE: institutional holders (13F)

13F holdings, latest reported quarter
5AM Venture Management, LLC
9,681,763 sh
$6.7M
Versant Venture Management, LLC
2,007,704 sh
$1.4M
BAKER BROS. ADVISORS LP
1,575,243 sh
$1.1M
VANGUARD CAPITAL MANAGEMENT LLC
763,882 sh
$529.4K
SPHERA FUNDS MANAGEMENT LTD.
678,928 sh
$470.7K

Congress trades in SKYE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SKYE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

SKYE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$103.0K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$128.2K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$14.6K position · as of 2026-05-31
0.0%
VANGUARD BALANCED INDEX FUND
$11.8K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$23.8K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$389.5K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Mr. Dhillon
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.4M
-$148.3K
$882.3K
-81%
n/a
2024
$6.1M
$2.8M
$2.2M
-30%
n/a
2023
$1.8M
$1.3M
$1.3M
-33%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $889.2K sold by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SKYE financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$38.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-545.84x
TTM operating cash flow over long-term 2021-12-31 (54 months older than the period end) plus current 2020-09-30 (69 months older than the period end)
Return on equity
-233.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-159.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-239.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$47.6M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term 2021-12-31 (54 months older than the period end) plus current 2020-09-30 (69 months older than the period end), minus cash 2026-06-30
FCF yield
-69.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$58.2M-$30.2M-$34.7M-$18.3M
Net income-$55.9M-$26.6M-$37.6M-$19.5M
EPS (diluted)-1.41-0.73-5.37-8.77
Operating cash flow-$43.1M-$25.2M-$14.0M-$12.7M
Cash$5.9M$68.4M$1.3M$1.2M
SEC XBRL, fiscal years, as known on 2026-10-28

SKYE Stock Sonar score 5/7 axes

Find similar shapesCompare

SKYE ranks highest on risk and compliance (59th percentile) and insider conviction (19th), and lowest on financial health (2nd), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
12
Inputs
  • Return on equity-233.9% · 15 pct, sector of 545
  • Return on assets-159.8% · 14 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-239.4% · 8 pct, sector of 576
Financial health
2
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-545.84x · 2 pct, sector of 371
Insider conviction
19
Inputs
  • Net Form 4 buying (codes P and S), 180d-$889K · 37 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
14
Inputs
  • Funds adding, latest quarter9 · 14 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
59
Inputs
  • Short interest, % of float+5.0% · 59 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SKYE filings, in plain words

Are Skye Bioscience insiders buying or selling SKYE?

In the 180 days to 2026-10-28, Skye Bioscience insiders were net sellers, a net $889.2K across purchases and sales reported on Form 4, by 2 sellers.

Read the full summary

In the 180 days to 2026-10-28, Skye Bioscience insiders were net sellers of SKYE, a net $889.2K across purchases and sales reported on Form 4 by 2 sellers. Most of that figure, $889.2K, came from a holder of 10% or more rather than an officer or director. None of the 30 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies